Diana Murakhovskaya
General Partner & Co-Founder @ The Artemis Fund
New York, United States
Diana Murakhovskaya is a seed investor at The Artemis Fund in New York focused on Health Care and Payments. Diana Murakhovskaya is the General Partner & Co-Founder at The Artemis Fund. Diana Murakhovskaya attended The Cooper Union for the Advancement of Science and Art.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries Diana Murakhovskaya invests in
Stages Diana Murakhovskaya invests in
Countries Diana Murakhovskaya invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 2 (40%)
- Payments 1 (20%)
- Software 1 (20%)
- Parenting 1 (20%)
- Consulting 1 (20%)
Stage
- Seed 4 (80%)
- Series A 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Salvo is emerging as the leader in helping GI providers leap into a hybrid-care vision of the future of medicine, providing brick & mortar clinics with an easy to implement continuous care platform that saves time, increases revenue and improves patient outcomes.The company has announced agreements with 771 GI’s, representing 15% of allindependent GI’s in the US, to deploy wraparound care for their clinic patients. Included in its customers are five of the largest GI practices in the country, together seeing over 1.1 million GI patients a year. Salvo provides the tech and care delivery for modern, interdisciplinary care to treat chronic conditions that have surged in cost and prevalence: --IBS and IBD (over 40M affected) -- GERD and Celiac (over 50M affected) --MASH/MASLD, what was previously called “fatty liver disease” (over 80M) --Obesity (over 100M) The care benefits patients (76% of patients reported improved symptoms, five accepted medical conference abstracts on outcomes), generates incremental profit for practices (over $2M EBITDA improvement for a 100 GI practice), and reduces total healthcare costs (79% drop in GI-related ER utilization). | $8.5M / Series A / Jan 22, 2026 | ||
| Salvo is emerging as the leader in helping GI providers leap into a hybrid-care vision of the future of medicine, providing brick & mortar clinics with an easy to implement continuous care platform that saves time, increases revenue and improves patient outcomes.The company has announced agreements with 771 GI’s, representing 15% of allindependent GI’s in the US, to deploy wraparound care for their clinic patients. Included in its customers are five of the largest GI practices in the country, together seeing over 1.1 million GI patients a year. Salvo provides the tech and care delivery for modern, interdisciplinary care to treat chronic conditions that have surged in cost and prevalence: --IBS and IBD (over 40M affected) -- GERD and Celiac (over 50M affected) --MASH/MASLD, what was previously called “fatty liver disease” (over 80M) --Obesity (over 100M) The care benefits patients (76% of patients reported improved symptoms, five accepted medical conference abstracts on outcomes), generates incremental profit for practices (over $2M EBITDA improvement for a 100 GI practice), and reduces total healthcare costs (79% drop in GI-related ER utilization). | $4.7M / Seed / Feb 10, 2025 | ||
| SimpliFed is a healthcare technology company that provides virtual maternal care focused on breastfeeding and baby feeding support for families. It offers a telehealth platform that connects parents with certified lactation and baby-feeding specialists, delivering personalized, evidence-based care from pregnancy through the postpartum period. Theplatform includes services such as feeding guidance, remote monitoring, mental health screenings, and ongoing support to improve maternal and infant health outcomes. SimpliFed works closely with healthcare providers and health plans, integrating its services into existing care systems to enhance access and continuity of care. Its approach emphasizes inclusive, judgment-free support, helping parents make informed decisions about feeding methods while addressing both physical and emotional well-being. | $4M / Seed / Feb 04, 2025 | ||
| We work with builders to manage their deal from acquisition to finance on one collaborative platform that allows all partners to access all information, analytics in real time. We help raise construction finance efficiently and easily through our marketplace. | Seed / Jan 20, 2024 | ||
| The Host Co. makes Airbnb’s shoppable. Guests can now walk into a rental and buy anything from the snacks in the fridge to the art on the walls. Plus we connect guests to services like alcohol delivery, in-home massage and locally curated gifts. Travelers are delighted with the new hotel-like amenities of their stay and hosts make more money fromevery booking. See how it works: www.thehost.co/introvideoThe details: - LGBTQ+ and female founded company. Annie Sloan (Facebook, Twitter. RGA) and Mikel Hubbard (HGTV, MTV, X8). - Beta is live in test Airbnb’s with 40% of guests buying products and 97% of guests opening the stores. - Public launch July 1 with a current waiting list and community of 8000 hosts. | $1.9M / Seed / Mar 02, 2022 |
Co-Investors
About The Artemis Fund
The Artemis Fund invests in female-founded, tech-enabled companies that help people build wealth and allow people to care for their families and communities in a more sustainable way.
The Artemis Fund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Adrienne Mangual
VP of Finance & Operations
|
|||
|
Diana Murakhovskaya
General Partner & Co-Founder
|
|||
Juliette Richert
Senior Analyst
|
|||
Stephanie Campbell
General Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Diana Murakhovskaya invest in?
Diana Murakhovskaya invests primarily in Health Care, Payments and Software startups, most often at Seed and Series A stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Diana Murakhovskaya?
Public channels for Diana Murakhovskaya include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Diana Murakhovskaya last invest?
The most recent investment recorded for Diana Murakhovskaya closed in Jan 2026. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
